Is Ruxolitinib cream available for the treatment of vitiligo?

Ruxolitinib cream, trade nameOpzelura, was approved in the United States in September 2021 for the treatment of mild to moderate atopic dermatitis (AD). It is the first topical Janus kinase inhibitor approved in the United States. In July 2022, ruxolitinib cream was approved for medical use in the United States for the treatment of vitiligo. On February 23, 2023, the European Medicines Agency (EMA) approved the marketing authorization of ruxolitinib cream for the treatment of non-segmental vitiligo, which is also sold under the trade name Opzelura. The original drug of ruxolitinib cream has not yet been marketed in China, so it cannot be included in medical insurance.